Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].
Pabinger I, Gastl G, Steurer M, Sormann S, Fillitz M, Friedl J, Geissler D, Geissler K, Greil R, Knöbl P, Kozek-Langenecker S, Krippl P, Kyrle P, Lang A, Linkesch W, Ludwig H, Müller M, Panzer S, Pittermann E, Thaler J, Weltermann A. Pabinger I, et al. Among authors: linkesch w. Wien Klin Wochenschr. 2012 Feb;124(3-4):111-23. doi: 10.1007/s00508-012-0123-3. Epub 2012 Mar 3. Wien Klin Wochenschr. 2012. PMID: 22382553 German.
[The use of erythropoiesis-stimulating proteins in anemic patients with malignant diseases].
Osterreichische Konsensus-Gruppe zum Einsatz von Erythropoese-stimulierenden Proteinen bei Chemotherapie-induzierter Anämie, unter der Schirmherrschaft der OGHO; Ludwig H, Auberger T, Burghuber OCh, Gnant M, Hopfinger G, Jäger U, Keil F, Kornek G, Linkesch W, Petru E, Pirker R, Pittermann E, Reinthaller A, Samonigg H, Steger G, Stockenhuber F, Studnicka M, Weiss G, Zielinski C. Osterreichische Konsensus-Gruppe zum Einsatz von Erythropoese-stimulierenden Proteinen bei Chemotherapie-induzierter Anämie, unter der Schirmherrschaft der OGHO, et al. Among authors: linkesch w. Wien Klin Wochenschr. 2008;120(15-16):507-13. doi: 10.1007/s00508-008-1007-4. Wien Klin Wochenschr. 2008. PMID: 18820857 German. No abstract available.
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Valent P, et al. Among authors: linkesch w. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7. Crit Rev Oncol Hematol. 2012. PMID: 21903413 Review.
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.
Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr WR, Krippl P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmüllner O, Greil R. Pleyer L, et al. Among authors: linkesch w. Ann Hematol. 2014 Nov;93(11):1825-38. doi: 10.1007/s00277-014-2126-9. Epub 2014 Jun 21. Ann Hematol. 2014. PMID: 24951123 Free PMC article. Clinical Trial.
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.
Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M. Thaler J, et al. Among authors: linkesch w. Leuk Res. 1997 Jan;21(1):75-80. doi: 10.1016/s0145-2126(96)00084-7. Leuk Res. 1997. PMID: 9029189 Clinical Trial.
Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study.
Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, Kyrle P, Knöbl P, Pabinger I, Thalhammer R, Schwarzinger I, Mannhalter C, Jaeger U, Heinz R, Linkesch W, Lechner K. Geissler K, et al. Among authors: linkesch w. Blood. 1997 Jul 15;90(2):590-6. Blood. 1997. PMID: 9226158 Free article. Clinical Trial.
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe W, Kühr T, Apfelbeck U, Fridrik M, Seewann H, Stöger M, Linkesch W, Pont J, Baldinger C, Hartner E, Bernhart M, Geissler D, Krieger O, Lang A, Lin W, Ludwig H, Duba C, Greil R, Gast G, Thaler J. Hilbe W, et al. Among authors: linkesch w. Leuk Lymphoma. 2001 Nov-Dec;42(6):1283-8. doi: 10.3109/10428190109097753. Leuk Lymphoma. 2001. PMID: 11911409 Clinical Trial.
224 results